Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IKF/AIO-QUINTIS trial of fruquintinib plus tislelizumab in MSS/pMMR metastatic colorectal cancer without active liver metastases
2024-519929-38-00Phase 2Authorised
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of fruquintinib and tislelizumab in colorectal cancer (CRC) and colorectal adenocarcinoma (2 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Progression-free survival. Planned start Jun 2025; status: authorised.
02
Drugs
fruquintinibtislelizumab
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on 2024-519929-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519929-38-00.